EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders

Lilianne Esmée van Stam, Bridget Jane Daisy Horstman, Pantep Angchaisuksiri, Manuel Carcao, Gili Kenet, Christoph Königs, Johnny Mahlangu, Maria Elisa Mancuso, Suely Meireles Rezende, Robert Francis Sidonio, Alok Srivastava, Guy Young und 2 weitere

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.01.006 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Lilianne Esmée van Stam und 13 weiteren Autor:innen. Beteiligte Einrichtung: Emma's Children Hospital, Amsterdam UMC location University of Amsterdam, Department of Pediatric Hematology, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Factor VIII, Antibodies, Monoclonal, Humanized, Hemophilia A, Antibodies, Bispecific. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Society on Thrombosis and Haemostasis Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It might take years for previously untreated patients (PUPs) with hemophilia A on emicizumab prophylaxis to receive 50 factor VIII (FVIII) exposures. This corresponds to the time at risk for FVIII inhibitors under conventional FVIII prophylaxis. During emicizumab prophylaxis, it is unknown whether additional treatment with regular FVIII doses promotes FVIII tolerance, unmasks inhibitors, or rather, induces them. Therefore, we conducted a survey to describe the current global perspectives and practices of hemophilia health care providers (HCPs) in PUPs with severe hemophilia A receiving emicizumab prophylaxis. In 2024, a survey was sent by email to 1193 hemophilia treatment centers, addressing the perceived inhibitor risk with emicizumab, the potential need for concomitant regular FVIII infusions, and the perceived parental willingness to use concomitant FVIII. In total, 102 pediatric HCPs (85% physicians, 13% nurses) from 38 countries participated. Perceived inhibitor risk data were available for 63 HCPs (62%). Compared with FVIII prophylaxis, the inhibitor risk on emicizumab was estimated to be higher by 13%, equal by 41%, lower by 32%, and unknown by 14%. Among 57 of 102 HCPs with clinical access to emicizumab for children with severe hemophilia A without inhibitors, 30 (53%) offered regular concomitant FVIII infusions. However, in the experience of the HCPs, approximately 45% of parents rejected this option due to concerns about intravenous access. Ultimately, global perspectives on FVIII inhibitor risk and concomitant FVIII use in PUPs on emicizumab prophylaxis are heterogeneous due to lack of evidence, indicating the need for further research to guide treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIAntibodies, Monoclonal, HumanizedHemophilia AAntibodies, BispecificFactor IXCoagulantsBlood Coagulation Factor InhibitorsHumansChildHealth Care SurveysTreatment OutcomePractice Patterns, Physicians'Risk FactorsAttitude of Health PersonnelRare DiseasesMale

Stichwörter der Autor:innen

factor VIIIhemophilia Aimmune tolerancesurveys and questionnaires

Substanzen

emicizumabFactor VIIIAntibodies, Monoclonal, HumanizedAntibodies, BispecificFactor IXF8 protein, humanCoagulantsBlood Coagulation Factor Inhibitors

Autor:innen und Institutionen

  • Emma's Children Hospital, Amsterdam UMC location University of Amsterdam, Department of Pediatric Hematology, Amsterdam, the Netherlands.
  • Faculty of Medicine Ramathibodi Hospital, Mahidol University, Department of Medicine, Bangkok, Thailand.
  • Hospital for Sick Children, University of Toronto, Division of Hematology/Oncology, Department of Pediatrics, Toronto, Ontario, Canada.
  • National Hemophilia Center, Sheba Medical Center & Amalia Biron Research Institute of Thrombosis & Hemost, Tel Aviv University, Tel Hashomer, Israel.
  • Goethe University, University Hospital Frankfurt, Department of Pediatrics and Adolescent Medicine, Clinical and Molecular Hemostasis, Frankfurt, Germany.
  • Hemophilia Comprehensive Care Centre, University of the Witwatersrand and National Health Laboratory Service, Department of Molecular Medicine and Hematology, Faculty of Health Sciences, Johannesburg, South Africa.

Förderung

  • International Society on Thrombosis and Haemostasis Inc

Zitieren

APA

van Stam, L. E., Daisy Horstman, B. J., Angchaisuksiri, P., Carcao, M., Kenet, G., Königs, C., Mahlangu, J., Mancuso, M. E., Rezende, S. M., Sidonio, R. F., Srivastava, A., Young, G., Fijnvandraat, K., & Gouw, S. C. (2026). The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.01.006

Vancouver

van Stam LE, Daisy Horstman BJ, Angchaisuksiri P, Carcao M, Kenet G, Königs C, et al. The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.01.006

BibTeX
@article{vanStam2026,
  author = {van Stam, Lilianne Esmée and Daisy Horstman, Bridget Jane and Angchaisuksiri, Pantep and Carcao, Manuel and Kenet, Gili and Königs, Christoph and Mahlangu, Johnny and Mancuso, Maria Elisa and Rezende, Suely Meireles and Sidonio, Robert Francis and Srivastava, Alok and Young, Guy and Fijnvandraat, Karin and Gouw, Samantha Claudia},
  title = {The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.01.006}
}
Kostenlos starten →